A sensitive HPLC-DAD method for the simultaneous determination of the anticancer lonidamine and five potential impurities in pure powder and tablet dosage forms was developed and validated. The impurities comprised by-products from thermal and photodegradation and potential secondary products from the drug synthesis. The structure of the main drug impurity was elucidated with the aid of GC-MS chromatography. A good resolution of all the analytes was achieved on a Gemini C18 column using isocratic elution and DAD detection. The optimal mobile phase consisted of a mixture of methanol–phosphate buffer (pH 3) (80:20, v/v). At a flow rate of 1.5 ml min-1, the total time of analysis was less than 15 min. The method was determined to be linear in the range of 10 – 200 g ml-1 for the quantitation of lonidamine and 0.5 – 50 g ml-1 for the related substances with a detection limit for the impurities of 0.15 g ml-1. Percentage recoveries ranged from 97.4 to 102.3 and 95.7 to 103.5 for the drug and impurities, respectively, and the relative precision values were less than 3.3%. Finally, the method was demonstrated to be robust, resistant to small variations of chromatographic variables such as pH, mobile phase organic/aqueous composition and column temperature.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Lonidamine and related impurities: HPLC analysis, stability profile and degradation pathways|
|Data di pubblicazione:||2013|
|Appare nelle tipologie:||1.1 Articolo in rivista|